Thomas Rupp

Managing Director

Thomas Rupp Consulting UG


My career in the oligonucleotide world began 1985 in the Research Group of Nobel Laureate Prof. Harald zur Hausen at the German Cancer Research Center in Heidelberg, Germany, when setting-up the the first core-facility for oligonucleotide manufacturing in Europe. At the same time I was complimenting my background in Chemistry with Virology and Molecular Biology; ​

1990-1993: Development of a DNA synthesiser and a DNA sequencer as member of the research group of Brian Sproat at EMBL, Heidelberg, Germany​

1993-1994: One year sabbatical at Loyola University, Chicago, IL, conducting Papillomavirus-related cancer research;​

1994-1998: Development of Ribozymes (therapeutic Hammerheads) manufacturing processes at Innovir GmbH, Göttingen, Germany, one of the early companies developing therapeutic oligonucleotides;​

1998-2002: Setup of the Spiegelmer (enantiomeric therapeutic Aptamer) manufacturing, QC and automation labs at Noxxon Pharma AG, Berlin, Germany.​

2002-2010: Global Field Application Specialist for oligonucleotide related products at GE Healthcare Europe.​

2010-2013: Internal Subject Matter Expert for the large scale oligonucleotide CMO Girindus, Cincinnati, USA;​

2013 – Independent CMC consultant at Thomas Rupp Consulting UG;​

2021 – Managing Director, Axolabs Berlin GmbH.​